NasdaqGS:BCRXBiotechs
BioCryst Pharmaceuticals (BCRX): Valuation Revisited After $90M Shelf Registration and R&D Chief Transition
Things are heating up for BioCryst Pharmaceuticals (BCRX) this week. The company just filed a $90.2 million shelf registration, which gives it the flexibility to raise cash by selling up to 11 million shares in the future. In addition, BioCryst’s chief research and development officer, Dr. Helen Thackray, will soon leave her role and move to an advisory position after September. Together, these moves point to possible changes in strategy and capital plans that investors will want to dig...